Pyrazolopyridinyl pyridine

Abstract

The present invention provides compounds of formula (I): pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.

1 . A compound of formula (I):  
     
       
         
         
             
             
         
       
     
     wherein: 
 R 1  is selected from the group consisting of halo, —NR 7 R 8 , Ay, —NR 7 Ay, Het, —NH(CH 2 ) m Het, and —NH(CH 2 ) l Ay; 
 each R 7  and R 8  are the same or different and are independently selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkylhydroxy, amine, alkylamine, alkylcarboxy, alkylcarboxamide, alkyl alkoxycarbonyl, alkylthioamide, alkylsulfonyl, alkylsulfonamide, alkylether, —(CH 2 ) l -cycloalkyl, —(CH 2 ) l NHCOR 9  and —(CH 2 ) m SO 2 NHCOR 9 ;  
 l is 1-6;  
 m is 0-6;  
 R 9  is H, alkyl, cycloalkyl, alkylhydroxy, amine, alkylamine, alkylcarboxy and alkylether;  
 Ay is aryl;  
 Het is a 5- or 6-membered heterocyclic or heteroaryl group;  
 R 2  is selected from the group consisting of H, halo, alkyl, cycloalkyl, alkenyl, cycloalkenyl, —NR 7 R 8 , —OR 7 , —OAy, —S(O) n R 7 , —S(O) n Ay, —R 10 NR 7 R 8 , —R 10 NR 7 Ay, Ay, Het, —NH(CH 2 ) m Het and —O(CH 2 ) m Het; n is 0, 1 or 2;  
 R 10  is alkyl or alkenyl;  
 
 Y is CH;  
 R 3  and R 4  are each independently selected from the group consisting of H, halo, hydroxy, alkyl, alkylhydroxy, alkylamine, alkylether, —OR 7 , —OAy, —NR 7 R 8 , —NR 7 Ay, carboxy, carboxamide, —SO 2 NHR 9 , Het and Ay; and  
 R 5  is halo;  
 wherein when Y is CH, R 3  is not —NR 7 Ay;  
 or a pharmaceutically acceptable salt thereof.  
 
   
   
       2 . The compound according to  claim 1  wherein R 1  is selected from the group consisting of —NR 7 R 8 , —NR 7 Ay, Ay, Het, —NH(CH 2 ) m Het, and —NH(CH 2 ) l Ay.  
   
   
       3 . The compound according to  claim 1  wherein R 1  is —NR 7 R 8 .  
   
   
       4 . The compound according to  claim 1  wherein R 2  is selected from the group consisting of —NR 7 R 8 , —OR 7 , —OAy, —S(O) n R 7 , —S(O) n Ay, —R 10 NR 7 R 8 , —R 10 NR 7 Ay, Ay, Het, —NH(CH 2 ) m Het and —O(CH 2 ) m Het.  
   
   
       5 . The compound according to  claim 4  wherein R 2  is selected from the group consisting of —NR 7 R 8  and Het.  
   
   
       6 - 7 . (canceled)  
   
   
       8 . The compound according to  claim 1  wherein R 3  and R 4  are each independently selected from the group consisting of H, hydroxy, alkyl, alkylhydroxy, alkylamine, alkylether, —NR 7 R 8 , —NR 7 Ay, carboxy and Ay.  
   
   
       9 . The compound according to  claim 8  wherein R 3  is selected from the group consisting of H, alkyl, alkylhydroxy, alkylamine, alkylether, and Ay.  
   
   
       10 . The compound according to  claim 8  wherein R 4  is H.  
   
   
       11 . The compound according to  claim 1  wherein R 5  is fluoro.  
   
   
       12 - 17 . (canceled)  
   
   
       18 . A pharmaceutical formulation comprising a compound according to  claim 1 .  
   
   
       19 . The pharmaceutical formulation according to  claim 18  further comprising a pharmaceutically acceptable carrier or diluent.  
   
   
       20 . The pharmaceutical formulation according to  claim 18  further comprising an antiviral agent selected from the group consisting of aciclovir and valaciclovir.  
   
   
       21 . A method for the treatment of a herpes viral infection selected from herpes simplex virus 1 and herpes simplex virus 2 in an animal, said method comprising administering to the animal a therapeutically effective amount of a compound according to  claim 1 .  
   
   
       22 . (canceled)  
   
   
       23 . A method for the treatment of a condition or disease associated with a herpes viral infection selected from heroes simplex virus I and herpes simplex virus 2 in an animal, comprising administering to the animal a therapeutically effective amount of the compound according to  claim 1 .  
   
   
       24 - 36 . (canceled)